| scholarly article | Q13442814 |
| P6179 | Dimensions Publication ID | 1053014290 |
| P356 | DOI | 10.1038/NMETH.2689 |
| P932 | PMC publication ID | 3851581 |
| P698 | PubMed publication ID | 24122041 |
| P5875 | ResearchGate publication ID | 257754973 |
| P50 | author | Elaine Mardis | Q5353251 |
| Malachi Griffith | Q37382147 | ||
| Adam C. Coffman | Q111971106 | ||
| Ron Bose | Q114289858 | ||
| Matthew B Callaway | Q125342085 | ||
| Obi Griffith | Q30503239 | ||
| P2093 | author name string | Li Ding | |
| Richard K Wilson | |||
| Christopher A Miller | |||
| David J Dooling | |||
| Timothy J Ley | |||
| David E Larson | |||
| Janakiraman Subramanian | |||
| Scott M Smith | |||
| Ramaswamy Govindan | |||
| Jason R Walker | |||
| Indraniel Das | |||
| James Koval | |||
| James M Eldred | |||
| James V Weible | |||
| Josh F McMichael | |||
| Nicholas C Spies | |||
| Runjun D Kumar | |||
| P2860 | cites work | PDTD: a web-accessible protein database for drug target identification | Q33320236 |
| DNA-Mutation Inventory to Refine and Enhance Cancer Treatment (DIRECT): A Catalog of Clinically Relevant Cancer Mutations to Enable Genome-Directed Anticancer Therapy | Q34002791 | ||
| Sequence analysis of mutations and translocations across breast cancer subtypes | Q34032470 | ||
| PubChem's BioAssay Database | Q34090643 | ||
| Trends in the exploitation of novel drug targets | Q34205159 | ||
| Genomics of Drug Sensitivity in Cancer (GDSC): a resource for therapeutic biomarker discovery in cancer cells | Q34313686 | ||
| The promise of genomics to identify novel therapeutic targets | Q35976369 | ||
| Large-scale prediction and testing of drug activity on side-effect targets | Q36059863 | ||
| The Comparative Toxicogenomics Database: update 2013. | Q36491395 | ||
| SuperTarget goes quantitative: update on drug-target interactions | Q38499993 | ||
| The druggable genome: an update | Q40362716 | ||
| PROMISCUOUS: a database for network-based drug-repositioning | Q41578922 | ||
| Molecular Targeted Agents and Biologic Therapies for Lung Cancer | Q82062699 | ||
| Gene ontology: tool for the unification of biology | Q23781406 | ||
| The protein kinase complement of the human genome | Q24324497 | ||
| Entrez Gene: gene-centered information at NCBI | Q24610128 | ||
| DrugBank 3.0: a comprehensive resource for 'omics' research on drugs | Q24612505 | ||
| Ensembl 2011 | Q24614810 | ||
| The Pfam protein families database | Q24619716 | ||
| InterPro in 2011: new developments in the family and domain prediction database | Q24620144 | ||
| Comprehensive molecular portraits of human breast tumours | Q24630844 | ||
| From pharmacogenomic knowledge acquisition to clinical applications: the PharmGKB as a clinical pharmacogenomic biomarker resource | Q24632079 | ||
| Update of TTD: Therapeutic Target Database | Q24643206 | ||
| SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions | Q24643366 | ||
| T3DB: a comprehensively annotated database of common toxins and their targets | Q24644620 | ||
| BindingDB: a web-accessible database of experimentally determined protein-ligand binding affinities | Q24675698 | ||
| Activating HER2 mutations in HER2 gene amplification negative breast cancer | Q27851987 | ||
| ChEMBL: a large-scale bioactivity database for drug discovery | Q28315179 | ||
| Prioritizing Potentially Druggable Mutations with dGene: An Annotation Tool for Cancer Genome Sequencing Data | Q28534371 | ||
| A side effect resource to capture phenotypic effects of drugs | Q29387552 | ||
| The druggable genome | Q29547361 | ||
| The Connectivity Map: using gene-expression signatures to connect small molecules, genes, and disease | Q29547614 | ||
| The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity | Q29547693 | ||
| The landscape of cancer genes and mutational processes in breast cancer | Q29614637 | ||
| Diverse somatic mutation patterns and pathway alterations in human cancers | Q29619825 | ||
| The clonal and mutational evolution spectrum of primary triple-negative breast cancers | Q29619914 | ||
| STITCH 3: zooming in on protein-chemical interactions | Q30002340 | ||
| P4510 | describes a project that uses | SQL | Q47607 |
| ggplot2 | Q326489 | ||
| P433 | issue | 12 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 1209-1210 | |
| P577 | publication date | 2013-10-13 | |
| P1433 | published in | Nature Methods | Q680640 |
| P1476 | title | DGIdb: mining the druggable genome | |
| P478 | volume | 10 |
| Q47674278 | "Personalized Cancer Therapy": A Publicly Available Precision Oncology Resource. |
| Q34543038 | A CRISPR Dropout Screen Identifies Genetic Vulnerabilities and Therapeutic Targets in Acute Myeloid Leukemia. |
| Q38838357 | A Network of Conserved Synthetic Lethal Interactions for Exploration of Precision Cancer Therapy. |
| Q33669451 | A c-Myc-regulated stem cell-like signature in high-risk neuroblastoma: A systematic discovery (Target neuroblastoma ESC-like signature). |
| Q40062073 | A genomic exploration identifies mechanisms that may explain adverse cardiovascular effects of COX-2 inhibitors |
| Q38381789 | A network-based drug repositioning infrastructure for precision cancer medicine through targeting significantly mutated genes in the human cancer genomes. |
| Q35671408 | A weighted and integrated drug-target interactome: drug repurposing for schizophrenia as a use case |
| Q28660588 | Advances in genome studies in plants and animals |
| Q33692066 | An imprinted non-coding genomic cluster at 14q32 defines clinically relevant molecular subtypes in osteosarcoma across multiple independent datasets |
| Q35801066 | An improved understanding of cancer genomics through massively parallel sequencing |
| Q37051436 | Automated identification of molecular effects of drugs (AIMED) |
| Q35244900 | BRAF V600E mutation in early-stage multiple myeloma: good response to broad acting drugs and no relation to prognosis |
| Q41009120 | Biomarkers of hippocampal gene expression in a mouse restraint chronic stress model |
| Q55031337 | Blood lipid-related low-frequency variants in LDLR and PCSK9 are associated with onset age and risk of myocardial infarction in Japanese. |
| Q61445781 | CCNE1 amplification is associated with poor prognosis in patients with triple negative breast cancer |
| Q33730180 | CVE: an R package for interactive variant prioritisation in precision oncology. |
| Q41138901 | Cancer Driver Log (CanDL): Catalog of Potentially Actionable Cancer Mutations |
| Q41156013 | CancerGD: A Resource for Identifying and Interpreting Genetic Dependencies in Cancer |
| Q41312671 | Cell-Type-Specific Translation Profiling Reveals a Novel Strategy for Treating Fragile X Syndrome |
| Q55717464 | Changing Trends in Computational Drug Repositioning. |
| Q33906319 | Choose and Use Your Chemical Probe Wisely to Explore Cancer Biology |
| Q30489035 | Clinical application of genomic profiling to find druggable targets for adolescent and young adult (AYA) cancer patients with metastasis. |
| Q54212643 | Combined Transcriptomics, Proteomics and Bioinformatics Identify Drug Targets in Spinal Cord Injury |
| Q91259857 | Combined chemosensitivity and chromatin profiling prioritizes drug combinations in CLL |
| Q33757949 | Comparative analysis of genes frequently regulated by drugs based on connectivity map transcriptome data. |
| Q91763928 | Comparative proteogenomic characterization of glioblastoma |
| Q27853385 | Comprehensive genomic analysis reveals FLT3 activation and a therapeutic strategy for a patient with relapsed adult B-lymphoblastic leukemia |
| Q38793593 | Computational approaches for the identification of cancer genes and pathways |
| Q37035513 | Concerted changes in transcriptional regulation of genes involved in DNA methylation, demethylation, and folate-mediated one-carbon metabolism pathways in the NCI-60 cancer cell line panel in response to cancer drug treatment |
| Q58756266 | Contribution of allelic imbalance to colorectal cancer |
| Q36434749 | DGIdb 2.0: mining clinically relevant drug-gene interactions. |
| Q52777528 | DGIdb 3.0: a redesign and expansion of the drug-gene interaction database |
| Q38922006 | Databases and tools for constructing signal transduction networks in cancer |
| Q33913055 | Detecting protein variants by mass spectrometry: a comprehensive study in cancer cell-lines |
| Q34529055 | Differences in somatic mutation landscape of hepatocellular carcinoma in Asian American and European American populations |
| Q47154705 | Differential prioritization of therapies to subtypes of triple negative breast cancer using a systems medicine method |
| Q90371841 | Dissecting the early steps of MLL induced leukaemogenic transformation using a mouse model of AML |
| Q37073617 | Divergent clonal selection dominates medulloblastoma at recurrence |
| Q92564494 | Diversity spectrum analysis identifies mutation-specific effects of cancer driver genes |
| Q35917239 | Drug Normalization for Cancer Therapeutic and Druggable Genome Target Discovery. |
| Q47205411 | Drug knowledge bases and their applications in biomedical informatics research. |
| Q64948190 | Drug repositioning of herbal compounds via a machine-learning approach. |
| Q36010298 | DrugGenEx-Net: a novel computational platform for systems pharmacology and gene expression-based drug repurposing |
| Q40392337 | DrugTargetInspector: An assistance tool for patient treatment stratification |
| Q58609423 | DrugThatGene: integrative analysis to streamline the identification of druggable genes, pathways, and protein complexes from CRISPR screens |
| Q57824478 | Druggability of Coronary Artery Disease Risk Loci |
| Q53712744 | Drugging the undruggable: gabapentin, pregabalin and the calcium channel α2δ subunit |
| Q64973181 | Dynamics of Dual Specificity Phosphatases and Their Interplay with Protein Kinases in Immune Signaling. |
| Q53721548 | Editorial: Strategies for cellular target identification of natural products |
| Q28550393 | Enhancements to the Rosetta Energy Function Enable Improved Identification of Small Molecules that Inhibit Protein-Protein Interactions |
| Q52332848 | Epigenetic alterations to Polycomb targets precede malignant transition in a mouse model of breast cancer |
| Q91386045 | Evidence that genes involved in hedgehog signaling are associated with both bipolar disorder and high BMI |
| Q47893147 | Evidence-Based Precision Oncology with the Cancer Targetome. |
| Q36994817 | Exploring Transcription Factors-microRNAs Co-regulation Networks in Schizophrenia |
| Q38345519 | Exploring hypertension genome-wide association studies findings and impact on pathophysiology, pathways, and pharmacogenetics |
| Q92136097 | Five-Feature Model for Developing the Classifier for Synergistic vs. Antagonistic Drug Combinations Built by XGBoost |
| Q57793316 | Frequent ESR1 and CDK Pathway Copy Number Alterations in Metastatic Breast Cancer |
| Q36496096 | Functional Genomic Landscape of Human Breast Cancer Drivers, Vulnerabilities, and Resistance |
| Q37452592 | Functional Genomics Identifies Tis21-Dependent Mechanisms and Putative Cancer Drug Targets Underlying Medulloblastoma Shh-Type Development. |
| Q38438981 | Functional and Genomic Features of Human Genes Mutated in Neuropsychiatric Disorders |
| Q38451584 | Functional genomics of candidate genes derived from genome-wide association studies for five common neurological diseases. |
| Q64990175 | FusionPathway: Prediction of pathways and therapeutic targets associated with gene fusions in cancer. |
| Q27319225 | G-DOC Plus - an integrative bioinformatics platform for precision medicine. |
| Q28550898 | Gene Network Rewiring to Study Melanoma Stage Progression and Elements Essential for Driving Melanoma |
| Q35698696 | GeneStoryTeller: a mobile app for quick and comprehensive information retrieval of human genes |
| Q55394663 | Genetic heterogeneity and actionable mutations in HER2-positive primary breast cancers and their brain metastases. |
| Q83231583 | Genetic interactions of G-quadruplexes in humans |
| Q39980133 | Genetics-directed drug discovery for combating Mycobacterium tuberculosis infection |
| Q35836071 | Genome Modeling System: A Knowledge Management Platform for Genomics |
| Q36546754 | Genome and transcriptome delineation of two major oncogenic pathways governing invasive ductal breast cancer development |
| Q57251981 | Genome-wide association study of intraocular pressure uncovers new pathways to glaucoma |
| Q63433067 | Genome-wide meta-analysis of depression identifies 102 independent variants and highlights the importance of the prefrontal brain regions |
| Q49341393 | Genomic Heterogeneity Within Individual Prostate Cancer Foci Impacts Predictive Biomarkers of Targeted Therapy |
| Q47573861 | Genomic analysis of follicular dendritic cell sarcoma by molecular inversion probe array reveals tumor suppressor-driven biology |
| Q33815746 | Genomic analysis of oesophageal squamous-cell carcinoma identifies alcohol drinking-related mutation signature and genomic alterations |
| Q40075332 | Genomic correlates of glatiramer acetate adverse cardiovascular effects lead to a novel locus mediating coronary risk |
| Q38646090 | HIT'nDRIVE: patient-specific multidriver gene prioritization for precision oncology. |
| Q33742810 | High number of kinome-mutations in non-small cell lung cancer is associated with reduced immune response and poor relapse-free survival |
| Q41557019 | Identification of a multi-cancer gene expression biomarker for cancer clinical outcomes using a network-based algorithm |
| Q47327357 | Identification of cancer genes that are independent of dominant proliferation and lineage programs |
| Q38597446 | Identification of drug candidates and repurposing opportunities through compound-target interaction networks |
| Q50043890 | Identification of potential therapeutic targets in prostate cancer through a cross-species approach. |
| Q61804657 | Identifying Potential Ageing-Modulating Drugs In Silico |
| Q41694630 | Identifying putative drug targets and potential drug leads: starting points for virtual screening and docking |
| Q36848243 | Immunomediated Pan-cancer Regulation Networks are Dominant Fingerprints After Treatment of Cell Lines with Demethylation. |
| Q93061511 | In Silico Toxicology Data Resources to Support Read-Across and (Q)SAR |
| Q38968891 | In silico frameworks for systematic pre-clinical screening of potential anti-leukemia therapeutics |
| Q36859396 | Integrated clinical, whole-genome, and transcriptome analysis of multisampled lethal metastatic prostate cancer. |
| Q30829479 | Integrated microRNA and messenger RNA analysis in aortic stenosis. |
| Q37054427 | Integrative analysis of cancer genes in a functional interactome |
| Q29248288 | Integrative meta-analysis identifies microRNA-regulated networks in infantile hemangioma |
| Q90576336 | Integrative omics analyses broaden treatment targets in human cancer |
| Q37345367 | Interactome-transcriptome analysis discovers signatures complementary to GWAS Loci of Type 2 Diabetes |
| Q36087896 | International genome-wide meta-analysis identifies new primary biliary cirrhosis risk loci and targetable pathogenic pathways |
| Q28597874 | Investigating core genetic-and-epigenetic cell cycle networks for stemness and carcinogenic mechanisms, and cancer drug design using big database mining and genome-wide next-generation sequencing data |
| Q89952388 | It's all druggable |
| Q36274247 | Large-scale bioactivity analysis of the small-molecule assayed proteome |
| Q34606998 | Leveraging the new with the old: providing a framework for the integration of historic microarray studies with next generation sequencing. |
| Q36109610 | MGDB: a comprehensive database of genes involved in melanoma. |
| Q38809010 | Mass spectrometric analysis of synaptosomal membrane preparations for the determination of brain receptors, transporters and channels |
| Q89243403 | Meta-analysis of genome-wide association studies for neuroticism in 449,484 individuals identifies novel genetic loci and pathways |
| Q95322476 | Metabolomics and Multi-Omics Integration: A Survey of Computational Methods and Resources |
| Q33865098 | Metastatic triple-negative breast cancer patient with TP53 tumor mutation experienced 11 months progression-free survival on bortezomib monotherapy without adverse events after ending standard treatments with grade 3 adverse events |
| Q36404935 | Methods to analyze big data in pharmacogenomics research |
| Q38682456 | Microarray analysis of copy-number variations and gene expression profiles in prostate cancer |
| Q30491801 | Molecular fingerprinting of principal neurons in the rodent hippocampus: A neuroinformatics approach |
| Q28073474 | Multi-Omics Studies towards Novel Modulators of Influenza A Virus-Host Interaction |
| Q35920105 | Multiplexed barcoded CRISPR-Cas9 screening enabled by CombiGEM. |
| Q41183987 | Multitype Network-Guided Target Controllability in Phenotypically Characterized Osteosarcoma: Role of Tumor Microenvironment. |
| Q31058925 | Mutation based treatment recommendations from next generation sequencing data: a comparison of web tools |
| Q34619293 | Mutational analysis of genes coding for cell surface proteins in colorectal cancer cell lines reveal novel altered pathways, druggable mutations and mutated epitopes for targeted therapy |
| Q35038084 | Mutational landscape of gastric adenocarcinoma in Chinese: implications for prognosis and therapy |
| Q59354957 | Mutations in and nucleotide excision repair genes are correlated with prognosis of hepatitis B virus-associated hepatocellular carcinoma |
| Q34499917 | NCG 5.0: updates of a manually curated repository of cancer genes and associated properties from cancer mutational screenings. |
| Q39929900 | Network-Based Identification and Prioritization of Key Regulators of Coronary Artery Disease Loci. |
| Q64272230 | Network-guided prediction of aromatase inhibitor response in breast cancer |
| Q42380034 | Neurochemical Markers in the Mammalian Brain: Structure, Roles in Synaptic Communication, and Pharmacological Relevance |
| Q35258057 | New concepts in breast cancer genomics and genetics |
| Q34474391 | OncoCis: annotation of cis-regulatory mutations in cancer |
| Q28650700 | Open pipelines for integrated tumor genome profiles reveal differences between pancreatic cancer tumors and cell lines |
| Q38898567 | OpenGeneMed: a portable, flexible and customizable informatics hub for the coordination of next-generation sequencing studies in support of precision medicine trials |
| Q44309573 | Opportunities for drug repositioning from phenome-wide association studies. |
| Q28652806 | Organizing knowledge to enable personalization of medicine in cancer |
| Q30964474 | PANDA: pathway and annotation explorer for visualizing and interpreting gene-centric data. |
| Q36762377 | PGMD: a comprehensive manually curated pharmacogenomic database |
| Q40139573 | Pan-cancer analysis of the extent and consequences of intratumor heterogeneity. |
| Q55017642 | PanDrugs: a novel method to prioritize anticancer drug treatments according to individual genomic data. |
| Q38875741 | Pathway and network-based strategies to translate genetic discoveries into effective therapies |
| Q91826369 | Pharmacogenomic landscape of patient-derived tumor cells informs precision oncology therapy |
| Q64900844 | Polypharmacy in an Elderly Population: Enhancing Medication Management Through the Use of Clinical Decision Support Software Platforms. |
| Q55258984 | Potential mechanism and drug candidates for sepsis-induced acute lung injury. |
| Q26748603 | Practical aspects of NGS-based pathways analysis for personalized cancer science and medicine |
| Q47133279 | Predicting drug-disease interactions by semi-supervised graph cut algorithm and three-layer data integration |
| Q47775156 | Prediction and Subtyping of Hypertension from Pan-Tissue Transcriptomic and Genetic Analyses |
| Q36731336 | Prognostic Molecular Subtypes of Low-Grade Cancer of the Appendix. |
| Q58767953 | RNA based individualized drug selection in breast cancer patients without patient-matched normal tissue |
| Q50872451 | RepurposeVS: A Drug Repurposing-Focused Computational Method for Accurate Drug-Target Signature Predictions |
| Q42363061 | Resources for Interpreting Variants in Precision Genomic Oncology Applications |
| Q112292282 | Retracted: Integrative bioinformatics approaches to map key biological markers and therapeutic drugs in Extramammary Paget's disease of the scrotum |
| Q34607063 | Revealing the inherent heterogeneity of human malignancies by variant consensus strategies coupled with cancer clonal analysis. |
| Q50421323 | Revisiting Antipsychotic Drug Actions Through Gene Networks Associated With Schizophrenia |
| Q27321859 | SciClone: inferring clonal architecture and tracking the spatial and temporal patterns of tumor evolution |
| Q94545588 | Shared Regulatory Pathways Reveal Novel Genetic Correlations Between Grip Strength and Neuromuscular Disorders |
| Q42146966 | Spatial and temporal clonal evolution during development of metastatic urothelial carcinoma |
| Q41969132 | Spatial heterogeneity in medulloblastoma |
| Q30278875 | SpeedSeq: ultra-fast personal genome analysis and interpretation |
| Q38207312 | Standardized decision support in next generation sequencing reports of somatic cancer variants |
| Q30982579 | Statistically identifying tumor suppressors and oncogenes from pan-cancer genome-sequencing data |
| Q45943046 | Structure-based prediction of ligand-protein interactions on a genome-wide scale. |
| Q28542977 | Surveying Recent Themes in Translational Bioinformatics: Big Data in EHRs, Omics for Drugs, and Personal Genomics |
| Q58101254 | SwissMTB: establishing comprehensive molecular cancer diagnostics in Swiss clinics |
| Q91235699 | Synthetic lethality as an engine for cancer drug target discovery |
| Q33640590 | Systematic analysis of the gerontome reveals links between aging and age-related diseases |
| Q52639487 | Systematic characterization of pan-cancer mutation clusters. |
| Q33766729 | Systematic discovery of mutation-specific synthetic lethals by mining pan-cancer human primary tumor data. |
| Q92971986 | Systematical identifications of prognostic meaningful lung adenocarcinoma subtypes and the underlying mutational and expressional characters |
| Q36301828 | TCLP: an online cancer cell line catalogue integrating HLA type, predicted neo-epitopes, virus and gene expression |
| Q35802177 | Targeting the schizophrenia genome: a fast track strategy from GWAS to clinic |
| Q27007413 | Ten years and counting: moving leucine-rich repeat kinase 2 inhibitors to the clinic |
| Q28818109 | The BioGRID interaction database: 2017 update |
| Q64254406 | The Pathway to Cancer Cachexia: MicroRNA-Regulated Networks in Muscle Wasting Based on Integrative Meta-Analysis |
| Q27499832 | The `dnet’ approach promotes emerging research on cancer patient survival |
| Q37712293 | The cancer cell map initiative: defining the hallmark networks of cancer |
| Q27026487 | The genetic basis of chronic mountain sickness |
| Q55294975 | The impact of pharmacokinetic gene profiles across human cancers. |
| Q58765339 | The prognostic effects of somatic mutations in ER-positive breast cancer |
| Q47906350 | Therapeutic targeting of ependymoma as informed by oncogenic enhancer profiling |
| Q34323926 | Tissue phosphoproteomics with PolyMAC identifies potential therapeutic targets in a transgenic mouse model of HER2 positive breast cancer. |
| Q64061141 | Towards embedding Caco-2 model of gut interface in a microfluidic device to enable multi-organ models for systems biology |
| Q52319664 | Transcription factors operate across disease loci, with EBNA2 implicated in autoimmunity |
| Q35136473 | Tumor evolution and intratumor heterogeneity of an epithelial ovarian cancer investigated using next-generation sequencing |
| Q35134186 | Unifying immunology with informatics and multiscale biology. |
| Q55411030 | Unveiling “Musica Universalis” of the Cell: A Brief History of Biological 12-Hour Rhythms. |
| Q61799981 | Using the drug-protein interactome to identify anti-ageing compounds for humans |
| Q38379725 | Using the neoadjuvant chemotherapy paradigm to develop precision therapy for muscle-invasive bladder cancer |
| Q52314490 | Viral induced oxidative and inflammatory response in Alzheimer's disease pathogenesis with identification of potential drug candidates: A systematic review using systems biology approach. |
| Q28652236 | Virus-host interactomics: new insights and opportunities for antiviral drug discovery |
| Q28551986 | Whole Body Melanoma Transcriptome Response in Medaka |
| Q48361292 | Whole exome sequencing reveals intertumor heterogeneity and distinct genetic origins of sporadic synchronous colorectal cancer |
| Q31148615 | XGR software for enhanced interpretation of genomic summary data, illustrated by application to immunological traits. |
| Q37437305 | dbCPG: A web resource for cancer predisposition genes |
| Q37529618 | iCAGES: integrated CAncer GEnome Score for comprehensively prioritizing driver genes in personal cancer genomes |
| Q110218459 | The Drug Gene Interaction Database | described by source | P1343 |
Search more.